The DeFi industry must address scalability, liquidity and gas issues before serving more users, said Eric Chen, CEO and co-founder of Injective Labs. While decentralized finance (DeFi) token prices may be going down, new forms of utility like liquid staking are on the rise and some believe that more people

Injective, a cross-chain DeFi protocol for derivatives trading, has announced the public launch of its mainnet today. It’s also rolling out a $120 million liquidity incentive program for traders, market makers, and DeFi projects. Derivatives Trading Protocol Injective Heads to Mainnet Injective Labs has announced the mainnet launch of

Injective (INJ) is an Ethereum-compatible front-running resistant completely decentralized cross-chain protocol. It not only supports existing Ethereum users but is also intended to help connect users from various blockchain networks together into a single crypto community. The interoperable backbone that powers Injective Protocol enables cross-chain interactions between sovereign blockchains. How

DeFi trading platform Injective is kicking off its mainnet launch today with a bang. The platform followed the launch with the rollout of a $120 million incentives program. Built using Cosmos, Injective is attempting to become DeFi's Swiss army knife of decentralized trading platforms by offering a suite

Injective Labs Inc., which offers decentralized trading services with support from the world’s largest cryptocurrency exchange, has hired Sullivan & Cromwell associate Brandon Ferrick as its first general counsel. Ferrick, who joined Injective after three years at Sullivan & Cromwell in New York, said in an email he’s

Back in December last year Injective launched the testnet for its DeFi protocols for cross-chain derivatives trading, with backing from giant crypto exchange Binance. It has now raised $10 million in a “party” funding round. Participating in the round was Pantera Capital, BlockTower, Hashed, Cadenza Ventures (formerly BitMex Ventures), CMS,